Cardiac hypertrophy, especially left ventricular hypertrophy (LVH), is a major compensatory mechanism in response to pressure overload derived from hypertension.
Also, tissue remodeling through LVH is known to lead to heart failure if the increased workload is sustained over a long period of time. In a nutshell, hypertension can result in hypertrophy which, if sustained, leads to heart failure. Hypertension is also a risk factor for vascular accidents leading to ischemia.
Endothelial cell (dys)function has been shown to play important roles in the pathophysiological events related to the establishment and progression of hypertensive heart disease. Nitric oxide (NO) production by endothelial cells inhibits the progression of cardiac hypertrophy, whereas endothelin generation promotes hypertrophy. 1 Actually, the imbalance between these two systems is one of the underlying causes of cardiac tissue remodeling. Antihypertensive drugs that increase NO generation or that inhibit endothelin production have been shown to decrease cardiac hypertrophy (mostly by decreasing LVH), thus preventing heart failure induced by a pressure overload. 2 However, despite intense research, drugs able to ameliorate hypertension and, at the same time, protect against the associated heart diseases are still lacking. A promising candidate in this area is iptakalim, a recently developed K + channel opener (KCO) that has been shown to be antihypertensive in different models of hypertension in rats, dogs, and humans. 3, 4 This issue of Cardiovascular Research brings an interesting contribution to the field of hypertension and heart disease, uncovering some new properties of iptakalim.
Gao and coworkers 5 show that iptakalim possesses antihypertrophic properties, preventing the progression of LVH to heart failure induced by pressure overload. They also show that iptakalim helps maintain several hemodynamic parameters, such as heart rate, blood pressure, and ventricular function. Additionally, iptakalim reduces myocardial and perivascular fibrosis as well as mRNA expression of two important molecular markers of heart failure, atrial natriuretic peptide and B-type natriuretic peptide. Their most interesting results concern the signaling pathway that might underlie the whole-organ effects. Gao However, no such evidence is yet present in the cardiovascular-related iptakalim literature.
From the data published in this and other related papers, it does seem that iptakalim is a drug that deserves a chance in the battle against cardiac diseases in the clinical setting. However, as mentioned above, all cardioprotective KCO (as well as cardioprotective interventions such as pre-and postconditioning) have thus far been shown to act upon mitoK ATP , not sarcK ATP . Therefore, until further proof is provided, it might be safer to bet that iptakalim is just another mitoK ATP agonist.
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